Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.

@article{Nanhwan2014ChronicTW,
  title={Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.},
  author={Manjyot K. Nanhwan and Shukuan Ling and Monica Kodakandla and Sven Nylander and Yumei Ye and Yochai Birnbaum},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  year={2014},
  volume={34 9},
  pages={2078-85}
}
OBJECTIVE In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in patients with acute coronary syndromes. In addition to P2Y12-receptor antagonism, ticagrelor prevents cell uptake of adenosine and has proven able to augment adenosine effects. Adenosine protects the heart against ischemia-reperfusion injury. We compared the effects of clopidogrel and ticagrelor on myocardial infarct size (IS). APPROACH… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…